Last reviewed · How we verify
Standard of Care: Methylprednisolone acetate
Standard of Care: Methylprednisolone acetate is a Corticosteroid Small molecule drug developed by Herbert Lindsley, MD. It is currently FDA-approved for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis), Allergic and dermatologic conditions, Respiratory inflammatory conditions.
Methylprednisolone acetate is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.
Methylprednisolone acetate is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors. Used for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis), Allergic and dermatologic conditions, Respiratory inflammatory conditions.
At a glance
| Generic name | Standard of Care: Methylprednisolone acetate |
|---|---|
| Sponsor | Herbert Lindsley, MD |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Dermatology |
| Phase | FDA-approved |
Mechanism of action
Methylprednisolone acetate works by entering cells and binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and proliferation, and suppression of inflammatory mediators. The acetate ester formulation provides sustained release, making it suitable for depot injections.
Approved indications
- Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)
- Allergic and dermatologic conditions
- Respiratory inflammatory conditions
- Intra-articular and soft tissue injection for localized inflammation
Common side effects
- Hyperglycemia
- Hypertension
- Osteoporosis (with chronic use)
- Immunosuppression/increased infection risk
- Mood changes, insomnia
- Adrenal suppression (with prolonged use)
- Local injection site reactions (if injected)
Key clinical trials
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock (PHASE2)
- TReatment for ImmUne Mediated PathopHysiology (PHASE2)
- Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients (PHASE2)
- A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard of Care: Methylprednisolone acetate CI brief — competitive landscape report
- Standard of Care: Methylprednisolone acetate updates RSS · CI watch RSS
- Herbert Lindsley, MD portfolio CI
Frequently asked questions about Standard of Care: Methylprednisolone acetate
What is Standard of Care: Methylprednisolone acetate?
How does Standard of Care: Methylprednisolone acetate work?
What is Standard of Care: Methylprednisolone acetate used for?
Who makes Standard of Care: Methylprednisolone acetate?
What drug class is Standard of Care: Methylprednisolone acetate in?
What development phase is Standard of Care: Methylprednisolone acetate in?
What are the side effects of Standard of Care: Methylprednisolone acetate?
What does Standard of Care: Methylprednisolone acetate target?
Related
- Drug class: All Corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: Herbert Lindsley, MD — full pipeline
- Therapeutic area: All drugs in Immunology, Rheumatology, Dermatology
- Indication: Drugs for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)
- Indication: Drugs for Allergic and dermatologic conditions
- Indication: Drugs for Respiratory inflammatory conditions
- Compare: Standard of Care: Methylprednisolone acetate vs similar drugs
- Pricing: Standard of Care: Methylprednisolone acetate cost, discount & access